US WorldMeds, announced Walgreens will stock LUCEMYRA (lofexidine) tablets in Walgreens pharmacies across the U.S., effective September 1. LUCEMYRA is the only FDA-approved, non-opioid, non-addictive treatment for relief of multiple symptoms of opioid withdrawal in adults and requires a valid prescription to be dispensed. Eligible patients covered by commercial insurance will pay $0 for a LUCEMYRA prescription. Patients without insurance coverage for LUCEMYRA may be eligible to pay $300 for a LUCEMYRA prescription. According to provisional data released in July by the National Center for Health Statistics, more than 93,000 people died from drug overdoses in 2020, a death toll jump of more than 21,000, or nearly 30%, far eclipsing the record set the prior year. More than 900,000 people have died of overdoses since the U.S. drug epidemic began in 1999, according to the Centers for Disease Control and Prevention. Overdose deaths involving opioids have continued to drive the death toll, accounting for 69,710 overdose deaths in 2020, up from 50,963 in 2019. Patients whose prescriptions will be paid for in part or in whole by Medicare, Medicaid, or any similar federal or state healthcare program, are not eligible for savings or rebates according to federal and state law. Patients must visit a participating pharmacy for savings or rebates on their LUCEMYRA prescriptions. Maximum benefits may apply. LUCEMYRA is a non-opioid prescription medicine used in adults to help with the symptoms of opioid withdrawal that may happen when stop taking an opioid suddenly. LUCEMYRA will not completely prevent the symptoms of opioid withdrawal and is not a treatment for opioid use disorder.